Diabetes Market Sees Advances In CGMs, Artificial Pancreas Systems, And Connectivity
The focus of the diabetes market is firmly on the development of an artificial pancreas, now within two or three years from becoming commercialized, and progress is going so well that several companies are in line to release a product. Meanwhile, digital health is increasingly playing a major role in diabetes care, and device manufacturers are investing in connectivity solutions to satisfy patient and consumer needs.
You may also be interested in...
US FDA approved the Eversense CGM System for continually measuring glucose levels in adults with diabetes for up to 90 days, and the company is working on clinical evidence to support a 365-day indication, as well as working with Roche and Beta Bionics to include its sensor technology in fully integrated artificial pancreas systems
The next-generation Intellis could strengthen Medtronic’s grip on the spinal cord stimulation market, where it already holds a 30.2% share.
Medtech start-ups continue to bring fresh ideas and new approaches to a market that is continually looking for better and cheaper treatment options. The device industry’s major trade association recently featured dozens of start-ups at its annual conference, and companies offering new solutions to battle chronic diseases were among the highlights.